Issue Date: March 26, 2012
Alcon Buys Into Eye Disease Drug
Alcon is paying Belgian biotech firm ThromboGenics $100 million up front for the right to commercialize the eye disease drug ocriplasmin outside the U.S. European regulatory authorities are currently considering the drug as a treatment for symptomatic vitreomacular adhesion, a disease that can cause visual distortion and central blindness. Ocriplasmin is a truncated form of plasmin that is delivered through a one-time injection in the eye.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society